What is Differentiated Thyroid Cancer Phase 3 Selumetinib?

Category: Others

false

Selumetinib is an oral small-molecule MEK inhibitor currently in clinical trial studies for non-small cell lung cancer (NSCLC), thyroid cancer, and uveal melanoma. MEK is part of the RAS/RAF/MEK/ERK pathway, which regulates proliferation, differentiation, migration, survival and angiogenesis.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
0

Commonly reported side effects and conditions associated with Differentiated Thyroid Cancer Phase 3 Selumetinib

Side effect Patients
Acid reflux 1
Elevated blood pressure 1
Elevated liver enzymes 1
Puffy eyes 1
Skin rash 1
Swelling in ankles 1

Duration

Stopped using Differentiated Thyroid Cancer Phase 3 Selumetinib

Duration Patients
1 - 6 months 1
Last updated:
There are no evaluations for Differentiated Thyroid Cancer Phase 3 Selumetinib.